Status of tissue expression and serum levels of HER2 in gastric cancer patients in japan

Hepato-Gastroenterology

Volumn 60, Issue 125, 2013, Pages 1083-1088

  Narita, Toru ^a   Seshimo, Akiyoshi ^a   Suzuki, Mamoru ^b   Murata, Jun ^c   Kameoka, Shingo ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Hachioji Digestive Disease Hospital   (Japan)

^c Asakadai Central General Hospital   (Japan)

Author keywords

Gastric cancer; HER2 neu; Serum HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SURGERY; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84885817942     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121022     Document Type: Article

References (17)

1. Akiyama T, Sudo C, Ogaware H, et al.: The product of the human c-erb-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232:1664-1646.
2. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712. (Pubitemid 19147683)
3. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182. (Pubitemid 17231334)
4. Tai W, Mahato R, Cheng K, et al.: The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146:264-275.
5. Yoshino I, Goedegebuure PS, Peoples GE, et al.: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994; 54:3387-3390. (Pubitemid 24225955)
6. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010; 376:687-697.
7. Carney WP, Neumann R, Lipton A, et al.: Potential clinical utility of serum HER-2/neu-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003; 49:1579-1598. (Pubitemid 37194212)
8. Luftner D, Cheli C, Mickelson K, et al.: ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers 2004; 19:175-182. (Pubitemid 39406238)
9. Japanese Gastric Cancer Association; Japanese classification of gastric carcinoma, 14th edn. Kanehara & Co. Ltd, Tokyo 2010. (In Japanese)
10. Hofmann M, Stoss O, Shi D, et al.: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797-805. (Pubitemid 351724903)
11. Takehana T, Kunitomo K, Kono K, et al.: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay, Int J Cancer 2002; 98:833-837. (Pubitemid 34286677)
12. Bang Y, H. Chung H, Xu J, et al.: Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27:15.
13. Yu GZ, Chen Y, Wang JJ: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009; 135:1331-1339.
14. Kushlinskii NE, Shirokii VP, Gershtein ES, et al.: Soluble fragment of HER2/neu receptor in the serum of patients with breast cancer with different levels of this protein expression in the tumor. Bull Exp Biol Med 2007; 143:449-451. (Pubitemid 47456578)
15. Kono K, Naganuma H, Sekikawa T, et al.: Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. Tumour Biol 200; 21:139-144.
16. Takehana T, Kunitomo K, Kono K, et al.: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98:833-837. (Pubitemid 34286677)
17. Tsigris C, Karayiannakis AJ, Syrigos KN, et al.: Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res 2002; 22:3061-3065. (Pubitemid 36069359)